dipyridamole has been researched along with Ischemic Stroke in 5 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Ischemic Stroke: Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 9.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 8.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "The aim of this study is to investigate the effect of gradual dipyridamole titration and the incidence of dipyridamole-induced headache in patients with ischemic stroke or transient ischemic attack (TIA)." | 5.51 | Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial. ( Cha, JK; Chang, DI; Chang, JY; Chung, JW; Hong, KS; Jung, KH; Kang, MK; Kim, BK; Kim, HY; Lee, KY; Lee, SJ; Park, JM; Park, MS; Rha, JH; Shin, DI; Yoon, BW, 2022) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 4.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, MK | 1 |
| Cha, JK | 1 |
| Chang, DI | 1 |
| Kim, HY | 1 |
| Chung, JW | 1 |
| Jung, KH | 1 |
| Hong, KS | 1 |
| Chang, JY | 1 |
| Rha, JH | 1 |
| Park, JM | 1 |
| Kim, BK | 1 |
| Lee, SJ | 1 |
| Park, MS | 1 |
| Lee, KY | 1 |
| Shin, DI | 1 |
| Yoon, BW | 1 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Lim, ST | 1 |
| Murphy, SJX | 1 |
| Murphy, SM | 1 |
| Coughlan, T | 1 |
| O'Neill, D | 1 |
| Tierney, S | 1 |
| Egan, B | 1 |
| Collins, DR | 1 |
| McCarthy, AJ | 1 |
| Lim, SY | 1 |
| Smith, DR | 1 |
| Cox, D | 1 |
| McCabe, DJH | 1 |
| Scalia, L | 1 |
| Calderone, D | 1 |
| Capodanno, D | 1 |
| Woodhouse, LJ | 1 |
| Appleton, JP | 1 |
| Christensen, H | 1 |
| Dineen, RA | 1 |
| England, TJ | 1 |
| James, M | 1 |
| Krishnan, K | 1 |
| Montgomery, AA | 1 |
| Ranta, A | 1 |
| Robinson, TG | 1 |
| Sprigg, N | 1 |
| Bath, PM | 1 |
2 reviews available for dipyridamole and Ischemic Stroke
| Article | Year |
|---|---|
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolyt | 2022 |
2 trials available for dipyridamole and Ischemic Stroke
| Article | Year |
|---|---|
Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial.
Topics: Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Headache; Humans; Ischemic At | 2022 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
1 other study available for dipyridamole and Ischemic Stroke
| Article | Year |
|---|---|
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta | 2022 |